Search clinical trials for: Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe]

Total 120 results

Kumamoto University

Completed

Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE-IVUS)

Coronary Artery Disease | Hypercholesterolemia

Japan
Organon and Co

Completed

A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)

Hypercholesterolemia
Organon and Co

Completed

A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)

Hyperlipidemia
Organon and Co

Completed

A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)

Hypercholesterolemia
Organon and Co
Merck Sharp & Dohme LLC

Completed

Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With Primary Hypercholesterolemia and Coronary Heart Disease (P03396)

Coronary Artery Disease | Atherosclerosis | Hypercholesterolemia
Organon and Co
Merck Sharp & Dohme LLC

Completed

Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With High Cholesterol (P03434)

Atherosclerosis | Hypercholesterolemia
GlaxoSmithKline

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin

Dyslipidemias | Dyslipidaemias

United States
Organon and Co

Completed

An Efficacy and Safety Study of Ezetimibe (MK-0653, SCH 58235) in Addition to Atorvastatin Compared to Placebo in Participants With Primary Hypercholesterolemia (MK-0653-013)

Hypercholesterolemia
Shanghai Jiao Tong University School of Medicine

Unknown

Atorvastatin Plus Ezetimibe on Coronary Plaque Progression (AEPP)

Coronary Artery Disease

China
Organon and Co
Merck Sharp & Dohme LLC

Terminated

Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)

Coronary Artery Disease | Atherosclerosis | Hypercholesterolemia
University of California, San Diego
Merck Sharp & Dohme LLC

Terminated

Ezetimibe in Patients Hypo-responsive to Statins

Coronary Artery Disease | High Cholesterol

United States
Abbott

Completed

Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood

Dyslipidemias | Coronary Heart Disease | Mixed Dyslipidemia | Combined (Atherogenic) Dyslipidemia

United States
Organon and Co

Completed

Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)

Hypercholesterolemia
Organon and Co

Completed

Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)

Hypercholesterolemia
Xijing Hospital

Unknown

Ezetimibe and Atorvastatin Therapy on TCFA

Coronary Artery Disease

China
Amgen

Completed

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3 (GAUSS-3)

Hyperlipidemia

Canada, Denmark, France, United States, Czechia, New Zealand, Australia, South Africa, Italy, United Kingdom, Netherlands, Germany, Norway
Esperion Therapeutics, Inc.

Completed

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C

Hypercholesterolemia

United States
Organon and Co

Completed

A Long-term Safety and Tolerability Study of Ezetimibe Plus Atorvastatin in Participants With Coronary Heart Disease, Multiple Risk Factors, or Hypercholesterolemia Not Controlled by Atorvastatin (P01418/MK-0653-032)

Hypercholesterolemia
Chong Kun Dang Pharmaceutical

Completed

CKD-391 Pharmacokinetic Study

Healthy

Korea, Republic of
Gregory Graf, PhD

Terminated

Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD

Nonalcoholic Fatty Liver Disease (NAFLD)

United States
Chong Kun Dang Pharmaceutical

Completed

CKD-391 Pharmacokinetic Study Phase I

Healthy
Organon and Co

Completed

Ezetimibe Plus (+) Simvastatin Versus Atorvastatin Comparative Study (0653A-092)(COMPLETED)

Hypercholesterolemia
Organon and Co

Completed

A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)

Hypercholesterolemia
Organon and Co

Completed

Vytorin (10/20 Or 10/40) Compared to Atorvastatin (10 mg or 20 mg) in Patients With Coronary Artery Disease (0653A-126)(COMPLETED)

Hypercholesterolemia
Yonsei University

Recruiting

Effect of High-intensity Statin With Ezetimibe COmbination theRapy Versus High-intensity sTatin Monotherapy After Percutaneous Coronary Intervention With Drug-eluting Stents; the ESCORT Trial

Coronary Artery Disease Requiring Coronary Revascularization With Newer Generation DES Implantation

Korea, Republic of
Organon and Co

Completed

Ezetimibe (+) Simvastatin vs. Atorvastatin Comparative Study in DM or Metabolic Syndrome Patients (0653A-093)

Hypercholesterolemia
Esperion Therapeutics, Inc.

Completed

A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy

Hyperlipidemias

United States
Daewon Pharmaceutical Co., Ltd.

Completed

Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A

Hypercholesterolemia, Dyslipidemia

Korea, Republic of
Organon and Co

Completed

Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019)

Hypercholesterolemia
Baylor College of Medicine
Merck Sharp & Dohme LLC

Completed

Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome. (Merck-123)

Metabolic Syndrome

United States
Chong Kun Dang Pharmaceutical

Completed

Clinical Trial to Evaluate the Efficacy and Safety of CKD-391

Hyperlipidemia

Korea, Republic of
Pfizer

Terminated

A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.

Dyslipidemia | Hyperlipidemia

United States
Amgen

Completed

LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 (LAPLACE-2)

Hyperlipidemia

United States, Denmark, France, Italy, Czechia, Taiwan, Switzerland, Korea, Republic of, Germany, Hong Kong, Netherlands, Australia, Belgium, Canada, Hungary, South Africa, Russian Federation, Spain, United Kingdom, Sweden, Mexico
NYU Langone Health
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Cholesterol Lowering and Residual Risk in Diabetes, Type 1 (CHORD1)

Type 1 Diabetes

United States
NewAmsterdam Pharma

Recruiting

Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies (TANDEM)

Dyslipidemias | Hypercholesterolemia | Familial Hypercholesterolemia | High Cholesterol | ASCVD

United States
Organon and Co

Completed

Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)

Diabetes Mellitus | Cardiovascular Disorder
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

Hypercholesterolemia

United States, France, Italy, Israel, United Kingdom, Austria, Canada, Norway
CHU de Quebec-Universite Laval
Canadian Institutes of Health Research (CIHR); Biovalorem

Recruiting

Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma

Pancreatic Cancer | Metastatic Cancer | Pancreatic Ductal Adenocarcinoma | Pancreas Cancer

Canada
Queen's University

Completed

Atorvastatin Versus Ezetimibe and Fenofibrate as a Lipid-lowering Strategy

Dyslipidemia | Vascular Disease

Canada
NYU Langone Health

Completed

CHOlesterol Lowering and Residual Risk in Type 2 Diabetes (CHORD)

Type 2 Diabetes

United States
Chong Kun Dang Pharmaceutical

Completed

CKD-391 DDI : Atorvastatin and Ezetimibe in Healthy Volunteers

Healthy

Korea, Republic of
Zhejiang Hisun Pharmaceutical Co. Ltd.

Unknown

Efficacy and Safety of HS-25 or in Combination With Atorvastatin in Chinese Adults With Primary Hypercholesterolemia (HS-25-C-01)

Primary Hypercholesterolemia
Yonsei University

Completed

Effect of Lipid Modifying Drugs on HDL Function in Patients With Hyperlipidemia

Hyperlipidemia

Korea, Republic of
UMC Utrecht

Completed

Effects of Ezetimibe on Postprandial Hyperlipidemia and Endothelial Function

Metabolic Syndrome

Netherlands
Organon and Co

Completed

Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)

Metabolic Syndrome | Hypercholesterolemia
The First Affiliated Hospital of Nanchang University

Active, not recruiting

Helicobacter Pylori and Lacidophilin Tablets in Combination With Vonorazan Dual Therapy

Helicobacter Pylori Infection

China
Annapoorna Kini

Completed

Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy (YELLOW)

Coronary Artery Disease

United States
Akrikhin
Russian National Atherosclerosis Society

Completed

Statin Monotherapy or Statins in Combination With Ezetimibe in Patients for Prevention of CVD (UNISON)

Cardiovascular Diseases | Lipid Metabolism Disorders

Russian Federation
Yonsei University

Recruiting

Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease; Randomized Comparison of LDL-cholesterol Targeting <70 Versus <55mg/dL; Ez-PAVE Trial

Atherosclerotic Cardiovascular Disease

Korea, Republic of
Chinese Academy of Medical Sciences, Fuwai Hospital

Recruiting

Comparison of Atorvastatin and Pitavastatin on the Effect of HbA1c in AMI Patients With Abnormal Glucose Metabolism (CAPE-AMI)

Glucose Metabolism Disorders | Acute Myocardial Infarction

China

3

Subscribe